News

The Misuse of Drugs (Medicinal Cannabis) Regulations 2019 (the Regulations) set the minimum quality standard that medicinal cannabis products and ingredients must meet before they can be supplied in New Zealand. Importers, manufacturers, and suppliers must apply for assessment and provide evidence to the Medicinal Cannabis Agency to verify that their products meet the minimum quality standard. Eqalis Full Spectrum CBD120 30 mL has been verified as meeting the minimum quality standard. More...

Looking for a role that combines professional satisfaction with an incredible lifestyle? At Taupō Health Centre, we are proud to provide high-quality, equitable healthcare to our community – and we would love you to join us. Our clinic is a busy General Practice with an on-site Urgent Care Clinic, caring for approximately for 11,000 enrolled patients, as well as providing care for casual patients. We also provide after-hours support on Saturdays and Public Holidays on a rostered basis in...

Insulin syringes: BD brand is moving to Embecta The BD brand of insulin syringes is being rebranded as “Embecta”. It is the same product, but the box looks different. The website has example pictures showing the change of in appearance of the boxes. > Insulin syringes: BD brand is moving to Embecta Promethazine 25 mg per ml, 2 ml ampoule All stock of this product in New Zealand (Pharmacode: 722952) is short-dated. A section 29 alternative has been listed. > Promethazine supply notice...

Below is the latest information on Pharmac consultations, notifications, and supply issues for Primary Care Prescribers for week 3 July 2026. It includes information on: New updates Resolved Supply Issues 03-07-2026 Pharmac Weekly Update to Prescribers in Primary Care Supply issue: candesartan (Candestar) (all strengths) Due to issues at the manufacturing plant, there is extremely limited supply of all strengths (4 mg, 8 mg, 16 mg, and 32 mg) of candesartan tablets (Candestar brand and...

Tēnā koe, We are pleased to share the refreshed New Zealand Cancer Action Plan 2026–2029 Te Mahere mō te Mate Pukupuku o Aotearoa 2026–2029. Cancer continues to place a significant and growing burden on Aotearoa New Zealand. More than 30,000 people are diagnosed each year, with this number expected to increase significantly in the coming decades as the population ages.While survival rates have improved, inequities in access and outcomes persist across different communities. This Plan sets a...

Our latest CPD options for you: Injectables for weight loss WEBINAR 7 July, 7.30pm. Jeremy Krebs on initiating and managing injectable therapies, focusing on contraindications, dose titration, maintenance dosing and intolerance management. Register here Managing lumbar and cervical spine presentations WEBINAR 14 July, 7.30pm. Otis Shirley will outline a practical primary care approach to common lumbar and cervical spine presentations, including recognising key pathologies, assessing red...